Contineum Therapeutics (NASDAQ:CTNM – Get Free Report) and Adherex Technologies (NASDAQ:FENC – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.
Risk & Volatility
Contineum Therapeutics has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500. Comparatively, Adherex Technologies has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500.
Earnings and Valuation
This table compares Contineum Therapeutics and Adherex Technologies”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Contineum Therapeutics | $50.00 million | 9.58 | -$59.98 million | ($1.73) | -7.36 |
| Adherex Technologies | $44.64 million | 8.16 | -$9.74 million | ($0.13) | -79.69 |
Adherex Technologies has lower revenue, but higher earnings than Contineum Therapeutics. Adherex Technologies is trading at a lower price-to-earnings ratio than Contineum Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Contineum Therapeutics and Adherex Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Contineum Therapeutics | N/A | -24.73% | -23.51% |
| Adherex Technologies | -6.09% | -5.71% | -2.37% |
Institutional and Insider Ownership
55.5% of Adherex Technologies shares are owned by institutional investors. 7.9% of Contineum Therapeutics shares are owned by company insiders. Comparatively, 10.7% of Adherex Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Contineum Therapeutics and Adherex Technologies, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Contineum Therapeutics | 1 | 1 | 4 | 0 | 2.50 |
| Adherex Technologies | 1 | 1 | 4 | 0 | 2.50 |
Contineum Therapeutics currently has a consensus price target of $22.17, suggesting a potential upside of 74.13%. Adherex Technologies has a consensus price target of $17.00, suggesting a potential upside of 64.09%. Given Contineum Therapeutics’ higher probable upside, equities analysts plainly believe Contineum Therapeutics is more favorable than Adherex Technologies.
Summary
Adherex Technologies beats Contineum Therapeutics on 7 of the 12 factors compared between the two stocks.
About Contineum Therapeutics
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.
About Adherex Technologies
Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.
Receive News & Ratings for Contineum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Contineum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
